Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28752184 | 0.87 | ALDH1A1 (0.48) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL30231055 | 0.87 | ALDH1A1 (0.54) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL694449 | 0.87 | ALDH1A1 (0.54) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL15778501 | 0.86 | ALDH1A1 (0.53) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL7651523 | 0.85 | ALDH1A1 (0.51) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL29559628 | 0.84 | CA1 (0.52) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL1028046 | 0.84 | CA1 (0.52) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL6300062 | 0.84 | CA12 (0.53) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL2948380 | 0.83 | LOXL2 (0.54) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL2480129 | 0.83 | STAT3 (0.41) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098548-A1 | PROTEIN DEGRADATION AGENT, PHARMACEUTICAL COMPOSITION COMPRISING SAME, USE THEREOF, AND METHOD | 四川科伦博泰生物医药股份有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12583839-B2 | PD-L1 antagonist compound | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| WO-2025201504-A1 | KAT6 INHIBITORS | BEIGENE (SUZHOU) CO., LTD. (CN) | 2025-10-02 | — | — | WO | disclosed |
| US-20250304535-A1 | KAT6 Inhibitors | BEIGENE SWITZERLAND GMBH (CH) | 2025-10-02 | — | — | US | disclosed |
| US-20250263402-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | disclosed |
| US-20250059183-A1 | PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST | SHANGHAI VISONPHARMA CO., LTD. (CN) | 2025-02-20 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-4446323-A1 | PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST | Shanghai Visonpharma Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| CN-118382625-A | Pyridine [4,3-d ] pyrimidines as TLR7/8 agonists | 上海维申医药有限公司 | 2024-07-23 | — | — | CN | disclosed |
| US-4997844-A | Compounds for the treatment of allergic or inflammatory diseases or shock conditions | ICI AMERICAS INC. (US) | 1991-03-05 | — | — | US | disclosed |
| EP-0403158-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0403159-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0179619-B1 | HETEROCYCLIC AMIDES | ICI AMERICAS INC. (US) | 1990-09-05 | — | — | EP | disclosed |
| US-4753962-A | HYPOGLYCEMIC, ANTIOBESITY AGENT | BEECHAM GROUP P.L.C. (GB) | 1988-06-28 | — | — | US | disclosed |
| US-4654371-A | ANTI-OBESITY, HYPOGLYCEMIA AGENTS | BEECHAM GROUP P.L.C. (GB) | 1987-03-31 | — | — | US | disclosed |
| EP-0179619-A1 | Heterocyclic amides | ICI AMERICAS INC. (US) | 1986-04-30 | — | — | EP | disclosed |
| US-4478849-A | HYPERGLYCEMIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1984-10-23 | — | — | US | disclosed |
| EP-0006735-B1 | SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | BEECHAM GROUP PLC (GB) | 1983-06-15 | — | — | EP | disclosed |
| EP-0006735-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | ALDH1A1 3930/4885CA12 2592/4885CA1 2874/4885 |
| US-20250263402-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GCGR | ALDH1A1 2478/4885CA12 4761/4885CA1 4621/4885 |
| US-20250304535-A1 | KAT6 Inhibitors | KAT6A, KAT6B, KAT2A | ALDH1A1 2832/4885CA12 2995/4885CA1 1153/4885 |
| US-12583839-B2 | PD-L1 antagonist compound | CD274, PDCD1LG2, PDCD1 | ALDH1A1 747/4885CA12 1349/4885CA1 1594/4885 |
| US-20250059183-A1 | PYRIDINE[4,3-D]PYRIMIDINE COMPOUND AS TLR7/8 AGONIST | TLR7, TLR8, TLR1 | ALDH1A1 2284/4885CA12 4875/4885CA1 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.